IN2014MN00740A - - Google Patents
Info
- Publication number
- IN2014MN00740A IN2014MN00740A IN740MUN2014A IN2014MN00740A IN 2014MN00740 A IN2014MN00740 A IN 2014MN00740A IN 740MUN2014 A IN740MUN2014 A IN 740MUN2014A IN 2014MN00740 A IN2014MN00740 A IN 2014MN00740A
- Authority
- IN
- India
- Prior art keywords
- proteins
- naglu
- mixture
- present
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
Abstract
The present invention provides compositions comprising an isolated mixture of recombinant human NaGlu proteins in which a substantial amount of the NaGlu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of NaGlu proteins vectors used in transgenesis and expression host cells harboring such vectors and methods of isolating and purifying the mixture of NaGlu proteins. The invention further provides methods of treating NaGlu associated diseases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161546248P | 2011-10-12 | 2011-10-12 | |
PCT/US2012/059708 WO2013055888A2 (en) | 2011-10-12 | 2012-10-11 | Recombinant human naglu protein and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN00740A true IN2014MN00740A (en) | 2015-05-22 |
Family
ID=48082738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN740MUN2014 IN2014MN00740A (en) | 2011-10-12 | 2012-10-11 |
Country Status (18)
Country | Link |
---|---|
US (3) | US20140255383A1 (en) |
EP (1) | EP2766477B1 (en) |
JP (1) | JP6329483B2 (en) |
KR (1) | KR20140108519A (en) |
CN (1) | CN103958676A (en) |
AU (1) | AU2012322811A1 (en) |
BR (1) | BR112014008873A2 (en) |
CA (1) | CA2852027A1 (en) |
CL (1) | CL2014000927A1 (en) |
CO (1) | CO7010783A2 (en) |
HK (1) | HK1200489A1 (en) |
IL (1) | IL232073A0 (en) |
IN (1) | IN2014MN00740A (en) |
MX (1) | MX2014004359A (en) |
RU (1) | RU2014117291A (en) |
SG (2) | SG11201401457SA (en) |
TW (1) | TW201321515A (en) |
WO (1) | WO2013055888A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5959795B2 (en) | 2006-08-18 | 2016-08-02 | アーメイゲン・テクノロジーズ・インコーポレイテッドArmagen Technologies, Inc. | Substances for blood-brain barrier delivery |
EP2997976A1 (en) | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
DK2485761T3 (en) | 2009-10-09 | 2019-05-06 | Armagen Inc | Methods and compositions for increasing iduronate-2-sulfatase activity in the CNS |
EP2613798B2 (en) | 2010-09-09 | 2018-01-24 | Synageva BioPharma Corp. | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients |
WO2012112681A1 (en) | 2011-02-15 | 2012-08-23 | Shire Human Genetic Therapies, Inc. | Methods for treating lysosomal acid lipase deficiency |
JP6329483B2 (en) * | 2011-10-12 | 2018-05-23 | シナジェバ・バイオファーマ・コーポレイションSynageva Biopharma Corp. | Recombinant human NAGLU protein and use thereof |
CA2857647C (en) | 2011-12-02 | 2022-04-19 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase a activity in the cns |
CN115120745A (en) * | 2013-05-15 | 2022-09-30 | 明尼苏达大学董事会 | Adeno-associated virus-mediated gene transfer to the central nervous system |
TW202332774A (en) * | 2013-10-23 | 2023-08-16 | 美商健臻公司 | Recombinant glycoproteins and uses thereof |
PT3143146T (en) * | 2014-05-14 | 2020-08-27 | Univ Auta²Noma De Barcelona | Adenoassociated virus vectors for the treatment of lysosomal storage disorders |
WO2015200675A1 (en) * | 2014-06-25 | 2015-12-30 | Shire Human Genetic Therapies, Inc. | Generation of mannose-6-phosphate containing recombinant alpha-n-acetyl glucosaminidase |
MX2017001898A (en) * | 2014-08-11 | 2017-04-11 | Shire Human Genetic Therapies | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes. |
JP2017531632A (en) | 2014-09-29 | 2017-10-26 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Methods for treating mucopolysaccharidosis type IIIB (MPSIIIB) |
CN104524662B (en) * | 2014-12-31 | 2017-02-22 | 迈得医疗工业设备股份有限公司 | Feeding mechanism for medical needle base assembling |
US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
US20190083583A1 (en) * | 2016-01-29 | 2019-03-21 | Alexion Pharmaceuticals, Inc. | Enzyme replacement therapy in mucopolysaccharidosis iiib patients |
IL305449A (en) | 2016-04-15 | 2023-10-01 | Univ Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
US10633705B2 (en) | 2016-10-14 | 2020-04-28 | Alexion Pharmaceuticals, Inc. | N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods |
CA3076036A1 (en) | 2017-09-22 | 2019-03-28 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
EP3692070A1 (en) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
CA3169548A1 (en) * | 2020-03-23 | 2021-09-30 | Haiyan Fu | Aav-naglu vectors for treatment of mucopolysaccharidosis iiib |
CN111718947B (en) * | 2020-06-18 | 2022-08-23 | 舒泰神(北京)生物制药股份有限公司 | Adeno-associated virus vector for treating type IIIA or IIIB mucopolysaccharidosis and use thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6825396B2 (en) | 1996-06-12 | 2004-11-30 | Board Of Trustees Operating Michigan State University | Methods for tissue specific synthesis of protein in eggs of transgenic hens |
US5897998A (en) | 1997-08-04 | 1999-04-27 | The University Of Georgia Research Foundation, Inc. | Method for manipulating avian eggs |
US7511120B2 (en) | 1997-10-16 | 2009-03-31 | Synageva Biopharma Corp. | Glycosylated G-CSF obtained from a transgenic chicken |
DE69842019D1 (en) | 1997-10-16 | 2011-01-05 | Synageva Biopharma Corp | TRANSGENIC BIRDS AND PROTEIN PRODUCTION |
US20040019923A1 (en) | 1997-10-16 | 2004-01-29 | Ivarie Robert D. | Exogenous proteins expressed in avians and their eggs |
US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
US6679165B2 (en) | 2002-05-22 | 2004-01-20 | Shiny Shih | Window adapted to a dater |
US20050142141A1 (en) * | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
ATE521701T1 (en) | 2003-01-22 | 2011-09-15 | Univ Duke | IMPROVED CONSTRUCTS FOR EXPRESSING LYSOSOMAL POLYPEPTIDES |
US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US20050090001A1 (en) | 2003-10-07 | 2005-04-28 | Parker Stephen H. | Cell lines and methods for producing proteins |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
EP1746902A4 (en) * | 2004-05-05 | 2007-06-13 | Univ Northeastern | Multi-lectin affinity chromatography and uses thereof |
CA2641070C (en) | 2006-02-06 | 2017-01-03 | Ramot At Tel-Aviv University Ltd. | Enzyme replacement therapy for treating lysosomal storage diseases |
CN101410408A (en) * | 2006-04-04 | 2009-04-15 | 希尔制药爱尔兰有限责任公司 | A process for concentration of a polypeptide |
WO2008091311A1 (en) | 2007-01-26 | 2008-07-31 | Synageva Biopharma Corp | Transgene expression in avians |
KR101343485B1 (en) * | 2008-01-07 | 2013-12-20 | 시나게바 바이오파르마, 코포레이션 | Glycosylation in avians |
WO2009131698A2 (en) * | 2008-04-23 | 2009-10-29 | Iowa State University Research Foundation, Inc. | PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF |
WO2011000958A1 (en) * | 2009-07-03 | 2011-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compounds targeting the cation-independent mannose 6-phosphate receptor |
NZ605871A (en) | 2010-06-25 | 2015-02-27 | Shire Human Genetic Therapies | Treatment of sanfilippo syndrome type b |
IL291554B2 (en) * | 2010-06-25 | 2024-02-01 | Shire Human Genetic Therapies | Cns delivery of therapeutic agents |
WO2012012742A2 (en) * | 2010-07-22 | 2012-01-26 | Shire Human Genetic Therapies, Inc. | Crystal structure of human alpha-n-acetylglucosaminidase |
EP2613798B2 (en) | 2010-09-09 | 2018-01-24 | Synageva BioPharma Corp. | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients |
JP6329483B2 (en) * | 2011-10-12 | 2018-05-23 | シナジェバ・バイオファーマ・コーポレイションSynageva Biopharma Corp. | Recombinant human NAGLU protein and use thereof |
-
2012
- 2012-10-11 JP JP2014535865A patent/JP6329483B2/en active Active
- 2012-10-11 IN IN740MUN2014 patent/IN2014MN00740A/en unknown
- 2012-10-11 US US14/350,644 patent/US20140255383A1/en not_active Abandoned
- 2012-10-11 MX MX2014004359A patent/MX2014004359A/en unknown
- 2012-10-11 EP EP12840612.1A patent/EP2766477B1/en active Active
- 2012-10-11 US US13/649,595 patent/US9579366B2/en active Active
- 2012-10-11 CA CA2852027A patent/CA2852027A1/en not_active Abandoned
- 2012-10-11 RU RU2014117291/10A patent/RU2014117291A/en not_active Application Discontinuation
- 2012-10-11 SG SG11201401457SA patent/SG11201401457SA/en unknown
- 2012-10-11 KR KR1020147012617A patent/KR20140108519A/en not_active Application Discontinuation
- 2012-10-11 WO PCT/US2012/059708 patent/WO2013055888A2/en active Application Filing
- 2012-10-11 AU AU2012322811A patent/AU2012322811A1/en not_active Abandoned
- 2012-10-11 BR BR112014008873-0A patent/BR112014008873A2/en not_active Application Discontinuation
- 2012-10-11 SG SG10201510106PA patent/SG10201510106PA/en unknown
- 2012-10-11 CN CN201280049876.4A patent/CN103958676A/en active Pending
- 2012-10-12 TW TW101137865A patent/TW201321515A/en unknown
-
2014
- 2014-04-10 IL IL232073A patent/IL232073A0/en unknown
- 2014-04-11 CL CL2014000927A patent/CL2014000927A1/en unknown
- 2014-05-08 CO CO14098853A patent/CO7010783A2/en unknown
-
2015
- 2015-01-27 HK HK15100907.5A patent/HK1200489A1/en unknown
-
2017
- 2017-02-10 US US15/429,309 patent/US20170216412A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL232073A0 (en) | 2014-05-28 |
JP6329483B2 (en) | 2018-05-23 |
MX2014004359A (en) | 2014-05-28 |
WO2013055888A2 (en) | 2013-04-18 |
CO7010783A2 (en) | 2014-07-31 |
RU2014117291A (en) | 2015-11-20 |
WO2013055888A3 (en) | 2013-06-13 |
KR20140108519A (en) | 2014-09-11 |
TW201321515A (en) | 2013-06-01 |
US20130095092A1 (en) | 2013-04-18 |
HK1200489A1 (en) | 2015-08-07 |
CA2852027A1 (en) | 2013-04-18 |
AU2012322811A1 (en) | 2014-05-01 |
EP2766477A4 (en) | 2015-07-15 |
CL2014000927A1 (en) | 2014-11-14 |
EP2766477B1 (en) | 2018-09-26 |
US20170216412A1 (en) | 2017-08-03 |
EP2766477A2 (en) | 2014-08-20 |
JP2014534962A (en) | 2014-12-25 |
SG11201401457SA (en) | 2014-05-29 |
US20140255383A1 (en) | 2014-09-11 |
US9579366B2 (en) | 2017-02-28 |
CN103958676A (en) | 2014-07-30 |
SG10201510106PA (en) | 2016-01-28 |
BR112014008873A2 (en) | 2020-09-15 |
NZ623690A (en) | 2016-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN00740A (en) | ||
PH12019500694A1 (en) | Factor viii compositions and methods of making and using the same | |
MX2021001494A (en) | Dkk1 antibodies and methods of use. | |
TW201613954A (en) | Interleukin-10 fusion proteins and uses thereof | |
EP2470559A4 (en) | Coagulation factor ix compositions and methods of making and using same | |
MY175708A (en) | Dna antibody constructs and method of using same | |
NZ705370A (en) | Fcγriib-specific fc region variant | |
MX359953B (en) | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein. | |
NZ616989A (en) | Therapeutic nuclease compositions and methods | |
IN2014DN10386A (en) | ||
IN2015KN00414A (en) | ||
WO2013078199A3 (en) | Methods for enhanced in vivo delivery of synthetic, modified rnas | |
WO2011123830A3 (en) | Alpha 1-antitrypsin compositions and methods of making and using same | |
MX2012011771A (en) | Aptamers to î²-ngf and their use in treating î²-ngf mediated diseases and disorders. | |
MX347535B (en) | Modified binding proteins inhibiting the vegf-a receptor interaction. | |
MX2014001383A (en) | Collagen 7 and related methods. | |
WO2013040093A3 (en) | Glucagon-like peptide-2 compositions and methods of making and using same | |
TN2012000511A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies | |
MD4548B1 (en) | CX3CR1-binding polypeptides | |
GB2496337A (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases | |
MX364623B (en) | MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO. | |
MY180953A (en) | Acyl-acp thioesterase | |
MX2015011846A (en) | Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases. | |
MX358598B (en) | Modified immune-modulating particles. | |
MX356317B (en) | Treatment of symptoms associated with female gastroparesis. |